Ysios et al. inject €19.4m into Minoryx

The round was backed by several new investors, including Kurma Partners, Roche Venture Fund, Idinvest Partners and Chiesi Ventures. Existing investor Caixa Capital Risc took part as well.

Minoryx will use the fresh funding to bolster its team, with a particular focus on R&D. The company intends to then move its lead project MIN-102 to clinical validation and to further develop a pipeline of non-competitive pharmacological chaperones – small molecules that serve as a molecular scaffolding for proteins to route correctly within a cell.

Previous funding
Caixa Capital Risc led a €1.6m round for Minoryx in January this year. The investment was designed to finance studies in potential drugs for the treatment of adrenoleukodystrophy, a disease that targets the nervous system and adrenal glands. Swiss charity Sanfilippo Foundation also took part in the round. Caixa's investment was drawn from Caixa Innvierte BioMed II, which launched in March 2014 with a €35m target.

Company
Founded in 2011 and headquartered in Mataró, near Barcelona, Minoryx produces drugs for patients suffering from genetic diseases that target the central nervous system. Its main product MIN-102 is currently at the pre-clinical stage.

People
Laia Crespo led the deal for Ysios.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Early-stage
• Healthcare
• Spain
• Ysios Capital
• IDInvest Partners (AGF Private Equity)